Stock analysts at HC Wainwright issued their Q3 2025 earnings per share estimates for shares of Intellia Therapeutics in a report issued on Wednesday, March 5th. HC Wainwright analyst M. Kapoor ...

Investment analysts at HC Wainwright cut their Q2 2025 earnings per share (EPS) estimates for shares of Avadel ...

Ten companies across mixed sectors also mirrored a broader market optimism, booking modest gains during the end of the ...

H.C. Wainwright analyst initiates coverage on Surf Air Mobility Inc. with a Buy rating and $12 price target, citing potential ...

Fintel reports that on March 7, 2025, HC Wainwright & Co. initiated coverage of Surf Air Mobility (NYSE:SRFM) with a Buy ...

H.C. Wainwright lowered the firm’s price target on Repare Therapeutics (RPTX) to $5 from $10 and keeps a Buy rating on the shares following the ...

H.C. Wainwright lowered the firm’s price target on BigBear.ai (BBAI) to $6 from $7 and keeps a Buy rating on the shares following the Q4 ...

Rusfertide could become a blockbuster therapy for polycythemia vera, H.C. Wainwright analyst Douglas Tsao wrote March 4 after the injectable hepcidin mimetic peptide hit its primary endpoint and all ...

Plug Power (Nasdaq: PLUG). From a high north of $3, shares of the hydrogen pioneer have been cut roughly in half, falling as ...

H.C. Wainwright notes that Neutral-rated Cassava Sciences (SAVA) has announced its financial and operational results for the fiscal year ended ...

LAVA Therapeutics reviews strategic options amid cost cuts. HC Wainwright downgrades stock, citing uncertainties over LAVA-1266 and possible business shifts.